Advertisement
PerkinElmer
PerkinElmer

The Scientist

» industry and ecology

Most Recent

image: CAR-T Therapies Get $1 Billion Boost

CAR-T Therapies Get $1 Billion Boost

By | July 1, 2015

The biotech firm Celgene inks a huge collaboration deal with Juno Therapeutics to develop and commercialize new cancer immunotherapies.

0 Comments

image: 1 + 1 = 1

1 + 1 = 1

By | July 1, 2015

Nutrient levels in soil don’t add up when food chains combine.

0 Comments

image: Intelligence Gathering

Intelligence Gathering

By | July 1, 2015

Disease eradication in the 21st century

0 Comments

image: Ravenous Invasive Worm Now in U.S.

Ravenous Invasive Worm Now in U.S.

By | June 25, 2015

Researchers have found the New Guinea flatworm, one of the world’s most invasive species, in Florida, putting native ecosystems at serious risk.

0 Comments

image: Organ-on-a-Chip Gets Big Pharma Boost

Organ-on-a-Chip Gets Big Pharma Boost

By | June 18, 2015

Johnson & Johnson agrees to use Emulate’s blood-clot device in three of its preclinical drug programs.

0 Comments

image: Climate Change Speeds Extinctions

Climate Change Speeds Extinctions

By | May 3, 2015

Species die-offs are expected to accelerate as greenhouse gases accumulate, according to a meta-analysis.

0 Comments

image: Follow the Funding

Follow the Funding

By | May 1, 2015

In times of budget belt-tightening at the federal level, life-science researchers can keep their work supported through private sources.  

8 Comments

image: Think Before You Fire

Think Before You Fire

By | May 1, 2015

Industry layoffs may save a few dollars, at the cost of losing the collective brainpower of thousands of scientists.

3 Comments

image: Bees Drawn to Pesticides

Bees Drawn to Pesticides

By | April 24, 2015

One study shows the insects prefer food laced with pesticides, while another adds to the evidence that the chemicals are harmful to some pollinators.

0 Comments

image: Drugmaker Teva Bids $40 Billion for Mylan

Drugmaker Teva Bids $40 Billion for Mylan

By | April 23, 2015

The Israel-based pharmaceutical company makes an unsolicited offer for a smaller, Netherlands-based rival as its main product faces competition from generics.

0 Comments

Advertisement

Popular Now

  1. Opinion: Too Many Mitochondrial Genome Papers
  2. Antibiotics and the Gut Microbiome
  3. Sex Differences in Pain Pathway
  4. The Sum of Our Parts
    Features The Sum of Our Parts

    Putting the microbiome front and center in health care, in preventive strategies, and in health-risk assessments could stem the epidemic of noncommunicable diseases.

Advertisement
Shimadzu Scientific
Shimadzu Scientific
Advertisement
The Scientist